Search Results - "Bruggenjurgen, B."

Medical resource use and costs of health care after acute stroke in Germany by Rossnagel, K., Nolte, C. H., Muller-Nordhorn, J., Jungehulsing, G. J., Selim, D., Bruggenjurgen, B., Villringer, A., Willich, S. N.

“…The purpose of this study was to determine the 12 months medical resource use following admission to hospital with acute stroke and to calculate costs from a…”
Get full text

The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing by Buhl, R., Kardos, P., Richter, K., Meyer-Sabellek, W., Brüggenjürgen, B., Willich, S. N., Vogelmeier, C.

“…SUMMARY Background: Budesonide/formoterol in a single inhaler is an effective therapy for asthma. We investigated whether adjustable maintenance dosing with…”
Get full text

Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study by Marston, X.L., Wang, R., Yeh, Y.-C., Zimmermann, L., Ye, X., Gao, X., Brüggenjürgen, B., Unverdorben, M.

“…The aim of the study was to compare the real-world effectiveness and safety in atrial fibrillation (AF) patients treated with edoxaban versus other oral…”
Get full text

Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany by Brüggenjürgen, B., Lindgren, P., Ehlken, B., Rupprecht, H.-J., Willich, S. N.

“…Patients with acute coronary syndrome without ST-segment elevation receiving clopidogrel in addition to acetylsalicylic acid (ASA) showed a 20% risk reduction…”
Get full text

House dust mite immunotherapy in Germany: real-world adherence to a subcutaneous allergoid and a sublingual tablet by Vogelberg, C., Brüggenjürgen, B., Richter, H., Jutel, M.

“…Summary Purpose Allergen immunotherapy (AIT) is the only disease-modifying treatment for allergic rhinitis (AR) and asthma (AA) with increasing efficacy…”
Get full text

Two-year Vascular Hospitalisation Rates and Associated Costs in Patients at Risk of Atherothrombosis in France and Germany: Highest Burden for Peripheral Arterial Disease by Smolderen, K.G, Wang, K, de Pouvourville, G, Brüggenjürgen, B, Röther, J, Zeymer, U, Parhofer, K.G, Steg, P.G, Bhatt, D.L, Magnuson, E.A

“…Abstract Objectives To obtain Western European perspectives on the economic burden of atherothrombosis in patients with multiple risk factors only (MRF),…”
Get full text

Subcutaneous specific immunotherapy: Economic implications from the perspective of statutory health insurance - a population based cost-effectiveness estimation by Reinhold, T, Willich, S, Brüggenjürgen, B

“…Specific immunotherapy is the only potentially curative therapy in patients with allergic rhinitis (AR) and allergic asthma (AA). The present study examined…”
Get full text

Cost impact of a non-invasive, portable device for patient self-administration of chronic migraine in a UK National Health Service setting by Brüggenjürgen, B., Baker, T., Bhogal, R., Ahmed, F.

“…Background Chronic migraine (CM) is a neurological disorder associated with substantial disability. Botulinum toxin type A (Botox) is an approved and effective…”
Get full text

Symptom-guided adjustable dosing asthma therapy with budesonide and formoterol in a single inhaler—The ATACO study by Buhl, R., Kardos, P., Baare, A., Richter, K., Meyer-Sabellek, W., Bruggenjurgen, B., Willich, S.N., Vogelmeier, C.

Get full text

Economic evaluation of BDP/formoterol fixed vs two single inhalers in asthma treatment by Brüggenjürgen, B, Ezzat, N, Kardos, P, Buhl, R

“…To cite this article: Brüggenjürgen B, Ezzat N, Kardos P, Buhl R. Economic evaluation of BDP/formoterol fixed vs two single inhalers in asthma treatment…”
Get full text

Effectiveness and safety of edoxaban in 27,333 patients from ETNA-AF with and without a history of intracranial haemorrhage after 2 years of treatment by Moser, J, Unverdorben, M, Wang, CC, Bruggenjurgen, B, Lee, BC, Chen, C, Pecen, L, Yamashita, T, De Caterina, R, Kirchhof, P

“…Abstract Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): This study was sponsored by Daiichi Sankyo, Inc. Medical…”
Get full text

Patient characteristics in German allergological practices - a nationwide survey by Reinhold, T, Lindig, C, Willich, S N, Brüggenjürgen, B

“…In Western societies a significant incidence and prevalence of allergic asthma and other allergic diseases is observable. The present study investigated…”
Get full text

EXPERTS’ PERCEIVED PATIENT BURDEN AND OUTCOMES OF KNEE-ANKLE-FOOT-ORTHOSES (KAFOs) VS. MICROPROCESSOR-STANCE-AND-SWING-PHASE-CONTROLLED-KNEE-ANKLE-FOOT ORTHOSES (MP-SSCOs) by Brüggenjürgen, Bernd, Braatz, Frank, Greitemann, Bernhard, Drewitz, Heiko, Ruetz, Axel, Schäfer, Michael, Seifert, Wolfgang, Steinfeldt, Friedemann, Weichold, Claudia, Yao, Daiwei, Stukenborg-Colsman, Christina

“…BACKGROUND: Patients with neuromuscular knee-instability assisted with orthotic devices experience problems including pain, falls, mobility issues and limited…”
Get full text

P2886Baseline stroke and bleeding risks in the global edoxaban treatment in routine clinical practice in patients with non-valvular atrial fibrillation programme (global ETNA-AF): first snapshot analysis by De Caterina, R, Bruggenjurgen, B, Kim, Y.-H, Koretsune, Y, Lee, B.-C, Levy, P, Yamashita, T, Wang, C.-C, Kirchhof, P

Get full text

P4803Prior antithrombotic therapy: a snapshot of 17,769 patients from the global edoxaban treatment in routine clinical practice in patients with non-valvular atrial fibrillation programme (global ETNA-AF) by De Caterina, R, Bruggenjurgen, B, Kim, Y.-H, Koretsune, Y, Lee, B.-C, Levy, P, Yamashita, T, Wang, C.-C, Kirchhof, P

Get full text

P1004The global ETNA-AF registry programme: snapshot baseline demographics and patient characteristics from more than 17,700 atrial fibrillation patients on edoxaban by Koretsune, Y, Yamashita, T, Kim, Y.-H, Wang, C.-C, Bruggenjurgen, B, Levy, P, Lee, B.-C, De Caterina, R, Kirchhof, P

Get full text

Health State In Patients With Atrial Fibrillation On New Oral Anticoagulants As Assessed With The New Eq-5d-5l Questionnaire At Baseline And 12-Month Follow-Up: Prefer In Af Registry by Brüggenjürgen, B, Schliephacke, T, Darius, H, De, Caterina R, Le, Heuzey J.Y, Reimitz, P.E, Schilling, R.J, Schwertfeger, M, Zamorano, J.L, Kirchhof, P

Get full text

Discontinuation And Hospitalisation Rates In Patients With Atrial Fibrillation: Follow-Up Results Of The Prefer In Af Registry by Brüggenjürgen, B, Schliephacke, T, Darius, H, De Caterina, R, Le Heuzey, J.Y, Pittrow, D, Reimitz, P.E, Schilling, R.J, Zamorano, J.L, Kirchhof, P

Get full text

Treatment Satisfaction In Patients With Atrial Fibrillation On New Oral Anticoagulants As Assessed With Pact-Q2 At Baseline And 12-Month Follow-Up: Prefer In Af Registry by Brüggenjürgen, B, Schliephacke, T, Darius, H, De, Caterina R, Le, Heuzey J.Y, Reimitz, P.E, Schilling, R.J, Schwertfeger, M, Zamorano, J.L, Kirchhof, P

Get full text

Prevention and private health insurance by Brüggenjürgen, B

Get more information